Clinical

No significant differences in efficacy or safety of 2 aspirin doses were found between male and female patients for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD).

Overall and site-specific colorectal cancer (CRC) had a negative association with the usage of aspirin.

Experts in dermatology presented ways in which biologic therapies can be given and the duration of treatment when used in pediatric patients with skin conditions.

Patients with myelodysplastic syndrome (MDS) in the treatment arm were more likely to achieve transfusion independence, but the difference vs placebo was not statistically significant.

Liposomal daunorubicin and cytarabine (CPX-351) was effective in relapsed acute myeloid leukemia, but long-term follow-up is needed to determine the extent of the agent's cardiotoxicity.

Ibrahim Aldoss, MD, of City of Hope, discusses promising phase 2 results of the WU-CART-007 trial, demonstrating high efficacy manageable safety for W-T7 in relapsed/refractory T-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL).

Pirtobrutinib led to improved outcomes compared with venetoclax in patients with relapsed chronic lymphocytic leukemia (CLL) following covalent Bruton tyrosine kinase inhibitor therapy.

Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, discusses the evolving treatment landscape for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma.

A small trial by investigators at the National Cancer Institute holds promise to bring personalized cell therapy into the solid tumor arena, after more than a decade of success in blood cancers.

A Danish study found that living in cities with fewer than 50,000 residents and in newer, owned, and less dense homes is associated with a lower risk of developing chronic obstructive pulmonary disease (COPD).

Jason Porter, MD, outlines the most significant unaddressed challenges in treating and managing non-small cell lung cancer as the field approaches the American Society of Clinical Oncology's 2024 annual meeting.

Stanley Goldstein, MD, discusses the differential diagnosis when considering CSU.

Giselle Mosnaim, MD, discusses the epidemiology that is associated with CSU.

William J. Gradishar, MD, analyzes current guidelines for identifying targetable mutations in breast cancer, explores strategies to enhance biomarker testing for mutations like PIK3CA or AKT1, and anticipates the growing influence of personalized medicine on the future of breast cancer treatment.

William J. Gradishar, MD, examines the impact of the CAPItello-291 phase III trial on NCCN breast cancer guidelines, comparing the investigated drug to other PI3K pathway inhibitors and discussing its potential to shape future treatment strategies.

Patients with both diabetes and atherosclerotic cardiovascular disease (ASCVD) have about 1.5 times higher total direct health care expenditures than those without diabetes.

A new study has found that myasthenia gravis does not affect the long-term prognosis of patients with thymoma.

A post-hoc analysis showed that zanubrutinib resulted in fewer adverse events compared with ibrutinib.

Patient outcomes in this trial were compared between the regimens of lenalidomide, bortezomib, and dexamethasone and daratumumab, lenalidomide, bortezomib, and dexamethasone for use against multiple myeloma (MM).

While there have been advances in screening technology, it is crucial to continue investing in emerging modalities and to ensure these advancements translate to clinical practice.

CMS recently launched a voluntary, nationwide dementia care program; the number of physicians who reported at least 1 symptom of burnout has dropped below 50% for the first time since the onset of the COVID-19 pandemic; diabetes drugs have all been in short supply over the last 18 months, partly due to people using them off label for weight loss.

Key considerations for transfusion requirements in patients with PNH are discussed by key opinion leaders.

Dr Haumschild and a panel of medical experts underscore financial considerations in PNH treatment.

Today, the FDA approved roflumilast cream 0.15% (Zorvye; Arcutis Biotherapeutics) for the treatment of mild to moderate atopic dermatitis in patients 6 years and older.

Metformin use is linked to improved survival rates in patients with ovarian cancer, particularly among those with diabetes and serous cancers, though further research is needed to confirm these findings.